A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson’s disease
| Autor: | A Dunac, MG Ceravolo, D Woitalla, Kallol Ray Chaudhuri, Nicola Pavese, Gomez, Esteban, Jc, JC Schuller, L Joeres, Mahnaz Asgharnejad, A Safavi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Levodopa Parkinson's disease Tetrahydronaphthalenes Combination therapy Thiophenes Severity of Illness Index Dopamine agonist Parkin 03 medical and health sciences 0302 clinical medicine Older patients 030502 gerontology Internal medicine Humans Medicine Pharmacology (medical) Aged Pharmacology business.industry Parkinson Disease Rotigotine General Medicine Middle Aged medicine.disease nervous system diseases Treatment Outcome Tolerability Dopamine Agonists Drug Therapy Combination Female Sleep 0305 other medical science business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 19:937-945 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1080/14656566.2018.1480721 |
| Popis: | PD0013 was a 6-month noninterventional study in clinical practice comparing effectiveness/tolerability of rotigotine+levodopa in younger (70 years) vs. older (≥70 years) Parkinson's disease (PD) patients.Patients previously received levodopa for ≥6 months as monotherapy/in combination with another dopamine-agonist (DA). Primary variable: Unified PD Rating Scale (UPDRS) Part-II change from baseline to end-of-observation-period (EOP).91 younger/99 older patients started rotigotine; 68 younger/62 older patients completed the study. Most switched from levodopa+another DA. Addition of rotigotine as first DA was more common in older patients (20.2% vs.15.4%). Mean ± SD rotigotine-exposure: 6.1 ± 3.4 mg/24h younger vs. 4.9 ± 2.4 mg/24h older. Eleven patients changed levodopa dose. At EOP, improvement in mean UPDRS-II was greater in younger patients (p = 0.0289). UPDRS-II responder-rate (≥20% decrease in UPDRS-II score) was higher in younger patients (42.3% vs. 25.9%). Improvement across age groups was similar on PD Sleep Scale-2 and Clinical Global Impressions-Improvement Scale. Adverse drug reactions (ADRs), and discontinuations because of ADRs, were more common among older patients. There were no new safety signals.Despite low rotigotine doses, when added to levodopa/switched from levodopa+another DA, rotigotine led to greater improvement in UPDRS-II in younger patients (70 years). Individual patient data revealed clinically meaningful improvements in UPDRS-II in both groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|